Press Release

27 May 2021

Available now! Whitepaper: Advancing Drug Discovery through DNA Encoded Library Technology!

CHENGDU, China, May 27th, 2021 HitGen and Fierce Biotech jointly release the Whitepaper: Advancing Drug Discovery through DNA-Encoded Library (DEL) Technology today. This whitepaper will provide the drug discovery community with an in depth dive of DEL technology and stimulate innovation in the field by describing HitGen’s experiences and knowledges on DEL design, synthesis, screening and expanded applications.
24 May 2021

Dorian and HitGen Announce Research Collaboration Focused on DNA-Encoded Library Based Drug Discovery

CHENGDU, China, May 24th, 2021-- Shanghai Stock Exchange listed company HitGen Inc. (“HitGen”) today announced that it has entered into a research collaboration agreement with Dorian Therapeutics, Inc.
13 May 2021

Coming Soon! Whitepaper: Advancing Drug Discovery through DNA-Encoded Library Technology！

Since its concept was conceived in 1992, DNA-encoded chemical libraries (DELs) have evolved into a valuable technology for hit identification in drug discovery.
06 April 2021

HitGen and BioAge Announce Research Progress in DNA-Encoded Library Based Drug Discovery Research Collaboration

On 6th April 2021, CHENGDU, China-- Shanghai Stock Exchange listed biotech company HitGen Inc. (“HitGen”) announced important research progress in a collaboration with BioAge Labs, Inc. (“BioAge”), a private biotechnology company developing targeted small molecules for the treatment of diseases of aging. The companies have conducted collaborative research to identify and develop novel small-molecule compounds against a high-value and challenging biological target that is a critical component of the innate immune system. Dysregulation of this target is closely linked to the underlying cause of severe diseases in elderly humans, such as Alzheimer's and cardiovascular disease.
10 March 2021

Lipigon expands collaboration with HitGen by selecting second target

Chengdu, China March 10th, 2021 Lipigon Pharmaceuticals AB (”Lipigon”), developer of therapeutics for lipid-related diseases, today announced that the company has expanded its agreement with the Shanghai STAR listed company HitGen Inc. (”HitGen”) to include a second novel target. With joint efforts, the aim is to develop a treatment for cardiometabolic disease.
01 March 2021

HitGen and UPPTHERA Enter Into Drug Discovery Research Collaboration

CHENGDU, China, March 1st, 2021 -- HitGen (688222.SH) today announced that it has entered into a drug discovery research collaboration with UPPTHERA Inc. to identify small molecule Hits against previous known-to-be undruggable targets and novel E3 ligase. HitGen will apply its platform technology, based on the design, synthesis and screening of DNA-encoded libraries (DEL) to discover compounds that bind to certain targets. The identified compounds will be exclusively licensed to UPPTHERA for further development. Under the terms of the agreement, HitGen will receive an undisclosed upfront payment, success fee, license/milestone fee from UPPTHERA.
21 December 2020

HitGen announces License Agreement with Merck & Co., Inc., Kenilworth, NJ USA to access compounds for potential development of a novel class of drugs

Chengdu, CHINA, December 21th 2020 HitGen Inc. is pleased to announce that HitGen and Merck & Co., Inc., Kenilworth, NJ USA, known as MSD outside the United States and Canada, expand their collaboration with a license to develop a novel class of drugs for an early target of high interest.
30 November 2020

Cedilla and HitGen Announce Research Collaboration Focused on DNA-Encoded Library Based Drug Discovery

CHENGDU, China--Shanghai Stock Exchange listed company HitGen Inc. (“HitGen”) today announced that it has entered into a research collaboration agreement with Cedilla Therapeutics, Inc. (“Cedilla”), a private biotechnology company developing targeted small molecules for the treatment of cancer and other diseases caused by protein dysregulation. The companies will conduct joint research to identify and develop drug candidates directed to a validated, high-value target in oncology that has remained beyond the reach of previous efforts.
10 November 2020

HitGen Licenses Its Trk/ROS1 Inhibitor HG030 to Baiyunshan for Development and Commercialisation in China

CHENGDU, CHINA, November 10 - HitGen Inc. (HitGen, 688222.SH) announces it has entered into a collaboration and licensing agreement with Guangzhou Baiyunshan Pharmaceutical Holdings Co., Ltd (Baiyunshan, 600332.SH/00874.HK) to develop and commercialise its HG030 programme in mainland China. Baiyunshan is a publically listed company in Shanghai and Hong Kong engaged in the pharmaceutical and healthcare industry. HG030 is a novel inhibitor for Trk/ROS1 discovered by HitGen, which received IND approval from China’s National Medical Products Administration (NMPA) in March 2020, and is entering Phase I clinical trial in China for patients with NTRK/ ROS1 gene fusion-positive cancers.
12 October 2020

HitGen to acquire Vernalis, a leader in structure-based drug discovery

CHENGDU, CHINA - HITGEN (688222.SH) announces it has entered into a definitive agreement with Ligand Pharmaceuticals Inc. (NASDAQ: LGND) to acquire Vernalis (R&D) Limited, Cambridge, UK-based world leaders in fragment and structure-based drug discovery research. The acquisition is for the entire issued share capital of Vernalis (R&D) Limited, for $25M in cash. The closing of this transaction is subject to customary conditions and approvals, expected to complete before the end of 2020.

News

Press Release

Thanks for reading!